Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 1:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 665 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phenylalanine (Phe) Clear all
Completed Phase 2 Interventional Results available

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

NCT00936936
View directory record Official record
Conditions
Testicular Cancer
Interventions
Gemcitabine, Docetaxel, Melphalan, Carboplatin, Mesna, Ifosfamide, Etoposide, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

NCT00925782
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection, Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

NCT00137995
View directory record Official record
Conditions
Lymphoma, Large-Cell, Diffuse
Interventions
Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
Drug · Procedure
Lead sponsor
Lymphoma Study Association
Other
Eligibility
18 Years to 65 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Timing of Levodopa Treatment in Parkinson's Disease

NCT00004733
View directory record Official record
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

NCT00008268
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 3 Interventional Results available

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

NCT00567567
View directory record Official record
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Isotretinoin, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate Liposome
Procedure · Drug · Radiation + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
169
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 128 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1 Interventional

Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies

NCT00824135
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Clofarabine, Stem Cell Transplantation, Hematopoietic, OKT3, Thiotepa, Melphalan, Mycophenolate mofetil, Rituximab, G-CSF
Drug · Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Parent Training in Child Safety Practices

NCT02934633
View directory record Official record
Conditions
Injury
Interventions
Keeping Baby Safe 2-DVD package, The Injury Prevention Program (TIPP) sheets
Behavioral
Lead sponsor
Oregon Center for Applied Science, Inc.
Industry
Eligibility
13 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 12, 2026, 1:19 PM EDT
Withdrawn Phase 1 Interventional

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

NCT04466475
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

KW-6002 to Treat Parkinson's Disease

NCT00006337
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 12, 2026, 1:19 PM EDT
Active, not recruiting Early Phase 1 Interventional

Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance

NCT07568275
View directory record Official record
Conditions
Septic Shock, Cirrhosis, Vasodilatory Shock, Acute Kidney Injury
Interventions
Giapreza
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

NCT00003661
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 54 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
17
States / cities
Gainesville, Florida • Jacksonville, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

NCT00943592
View directory record Official record
Conditions
Advanced Hematologic Malignancies, Leukemia, Preleukemia
Interventions
Clofarabine, Melphalan, Campath, Stem Cell Transplant
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Not applicable Interventional

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

NCT00152126
View directory record Official record
Conditions
Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions
Stem Cell Transplantation, Busulfan, Melphalan
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2009 · Synced Oct 12, 2026, 1:19 PM EDT
Withdrawn Not applicable Interventional

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

NCT02507076
View directory record Official record
Conditions
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
Interventions
isolated limb perfusion, melphalan, quality-of-life assessment
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia

NCT01005576
View directory record Official record
Conditions
Severe Thalassemia
Interventions
Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Year to 16 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single-Group Study to Evaluate the Effects of an Eyelash Serum on Improving Eyelash Growth

NCT06125730
View directory record Official record
Conditions
Eyelash Growth
Interventions
DIME Beauty Eyelash Boost Serum
Other
Lead sponsor
Dime Beauty Co.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 12, 2026, 1:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

NCT00793650
View directory record Official record
Conditions
Cancer, Multiple Myeloma
Interventions
Bortezomib, Melphalan, Autologous PBSC Transplant
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

NCT01323517
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Melphalan and Dactinomycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

NCT02497404
View directory record Official record
Conditions
Leukemia, Erythroblastic, Acute, Myelodysplastic Syndromes
Interventions
5-Azacytidine, Fludarabine, Melphalan, Alemtuzumab, Total Body Irradiation
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00182793
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, cyclophosphamide, melphalan, thiotepa, adjuvant therapy, autologous-autologous tandem hematopoietic stem cell transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 12, 2026, 1:19 PM EDT
Completed Phase 3 Interventional

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

NCT00020501
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
FOLFIRI regimen, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, melphalan, hyperthermia treatment
Drug · Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 12, 2026, 1:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation

NCT05967741
View directory record Official record
Conditions
Platelet Aggregation, Spontaneous, Vascular Thrombosis
Interventions
Erythritol, Aspartame
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 12, 2026, 1:19 PM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients

NCT00583622
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Bevacizumab, Carboplatin, Docetaxel, Gemcitabine, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 12, 2026, 1:19 PM EDT